At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
CC-220 +4 moredrug
Likely dose
CC-220 0.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
In Brief
A Phase 2 clinical trial evaluating CC-220 and Placebo for Systemic Lupus Erythematosus. Completed, enrolled 42 participants across 35 sites.
Detailed Summary
The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Lupus Erythematosus
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartSep 2014
Primary CompletionSep 2018
TodayJul 2026
First PostedJul 9, 2014
Enrollment StartSep 16, 2014
Primary CompletionSep 25, 2018
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 12.0 years ago
Interventions
CC-220drug
0.3 mg oral capsules once every other day with or without food
CC-220drug
Subjects will receive 0.3 mg oral capsules every day with or without food
CC-220drug
CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
CC-220drug
CC-220 oral capsule 0.6 mg QD with or without food
Placebodrug
Matching oral placebo daily